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Abstract

Biocatalysis

Conclusions

Malbrancheamide (Figure 1) is a fungal natural product with significant
vasorelaxation effects and potential as a cardiovascular therapeutic. The
dichlorination of the indole ring is key for its biological activity, and this
transformation is performed by the flavin dependent halogenase (FDH)
MalA (Figure 2). This enzyme utilizes a proposed chloramine lysine
intermediate to iteratively and selectively chlorinate its natural substrate
premalbrancheamide. Halogenases can provide orthogonal selectivity to
many chemical methods, making them useful for pharmaceutical
applications, while providing selective methods for late-stage
functionalization.

Initial high throughput screening was performed at Novartis to investigate MalA’s
substrate scope. In vitro enzymatic reactions were carried out on select nonproprietary compounds which showed activity. These were optimized by varying
volume and concentration of halogenase, reductase, substrate, and volume.

The flavin dependent halogenase MalA is a versatile enzyme for selective
halogenation (Figure 7) and late stage C—H functionalization of complex
substrates by electrophilic aromatic substitution.
Reactions with unnatural substrates were optimized and scaled up to
produce enough material for full characterization. The product of 2-217
(Figure 4) was found to be halogenated on C6 of the indole ring.

Figure 4. Reaction of Novartis 2-217 under brominating conditions with
the wild type MalA to brominate the oxindole C6 position

Reactions were extracted with ethyl acetate, and purified by HPLC. LC/MS was used
to confirm halogenation, while NMR was used to determine the location of the
halogenation (Figure 4).

Screening of the S129A/P85S mutant found six hits out of 20 substrates
screened. This shows that the S129A/P85S is useful for halogenation, as
well as reactivity on compounds which didn’t show halogenation with the
wild type enzyme.

Mutant Screening
Figure 1. Native reaction of MalA
Figure 2. MalA bound to FAD(orange),
premalbrancheamide, (pink), Cl- (green),
and lysine (cyan)

This investigation focuses on the substrate scope of the halogenase on
complex pharmaceutically relevant substrates in collaboration with the
Novartis Institutes for Biomedical Research. The bromination and
chlorination reaction conditions were optimized, and the products were
structurally characterized by NMR spectroscopy to gain further
understanding of the versatility of the wild type enzyme and its mutants.

S129A/P85S MalA (Figure 5) mutant
reactions were performed on compounds
sent from the Novartis library. These
reactions were screened by LC/MS for
halogenation (Figure 6).
Figure 5. MalA wild-type (teal) and
S129A/P85S (navy) overlaid, with
premalbrancheamide bound
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Figure 7. Selectivity of MalA mutants on the natural
premalbrancheamide substrate performed by Amy Fraley
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Due to the importance of halogenation in drug design , new methods of
selective and efficient halogenation can provide further means of tailoring
therapeutics, as many chemical methods lack selectivity. Nature has
evolved efficient methods of performing the most chemically challenging
reactions under benign catalytic conditions, allowing enzymes to perform
these reactions with exquisite site selectivity.
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Figure 3. MalA EAS reaction mechanism with chloramine lysine intermediate

MalA is an FDH which halogenates via electrophilic aromatic substitution
through a proposed chloramine lysine intermediate2 (Figure 3). This
intermediate prevents performing nonselective halogenation through
hypohalous acid. Due to the versatility of the enzyme, MalA can
halogenate a range of unnatural substrates.
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Figure 6. Mutant MalA S129A/P85S screen with Novartis compounds

